This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:mp [06.11.2018] – [Background and scientific rationale for the therapy] sallieq | home:mp [05.10.2019] – [Success rates noted for 5 diagnoses] sallieq | ||
---|---|---|---|
Line 237: | Line 237: | ||
{{section>: | {{section>: | ||
+ | |||
+ | |||
===== Stopping the Protocol ===== | ===== Stopping the Protocol ===== | ||
Line 249: | Line 251: | ||
+ | {{tag>MP summary}} | ||
+ | ===== Data ===== | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | ==== Response in 5 diagnoses ==== | ||
+ | |||
+ | | ||
+ | |||
+ | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
+ | |||
+ | Sarcoidosis success 75.8% | ||
+ | |||
+ | Chronic Fatigue Syndrome success 60.1% | ||
+ | |||
+ | Lyme disease success 66.9% | ||
+ | |||
+ | Rheumatoid arthritis success 69.2% | ||
+ | |||
+ | Fibromyalgia success 64.2% | ||
+ | |||
+ | All Other Th1 disease success 59.8% | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||